血浆MMP-9升高与肺功能加速下降及COPD发生的关联:前瞻性队列与孟德尔随机化研究
该研究包含前瞻性队列和两样本孟德尔随机化两部分:1328例基线分析、1034例完成2年随访。结果显示基线血浆MMP-9升高与慢性呼吸道症状、重度肺气肿及气体陷闭相关,并与FEV1和FVC加速下降、急性加重发生率升高及正常肺功能者进展为COPD相关;孟德尔随机化提示遗传预测的MMP-9表达与FEV1、FVC呈负向关联。
要点
- 基线血浆MMP-9升高与慢性呼吸道症状、重度肺气肿和气体陷闭相关。
- 血浆MMP-9每升高1个SD,FEV1多下降6.4 mL/年、FVC多下降18.0 mL/年。
- 基线肺功能正常者中,血浆MMP-9升高与进展为COPD相关(校正OR=1.93)。
核心结论
- 纵向队列与孟德尔随机化研究提示MMP-9可能在肺功能下降和肺功能定义的COPD发生中起因果作用。
研究设计与样本
- 研究分两部分:前瞻性队列研究分析循环MMP-9与呼吸健康结局的关联,基线纳入1328例,1034例(78%)完成2年随访。
- 第二部分为两样本孟德尔随机化研究,评估遗传预测的MMP-9表达与肺功能之间的因果效应。
- 队列参与者基线完成问卷、肺功能检查和胸部CT并提供血样,随访每年进行。
主要发现
- 基线血浆MMP-9较高与慢性呼吸道症状、重度肺气肿和气体陷闭相关。
- 2年随访期间,血浆MMP-9每升高1个SD,与支气管舒张前FEV1加速下降相关(校正差值=6.4 [95%CI: 0.7-12.1] mL/年)。
- 血浆MMP-9每升高1个SD,与FVC加速下降相关(校正差值=18.0 [95%CI: 7.6-28.5] mL/年),并与急性加重发生率升高相关。
- 基线肺功能正常者中,血浆MMP-9较高与进展为肺功能定义的COPD相关(校正OR=1.93,95%CI: 1.05-3.57)。
- 孟德尔随机化研究显示遗传预测的MMP-9表达与FEV1和FVC呈负向关联,结果与队列研究相似。
临床怎么用
- 对有慢性呼吸道症状或肺气肿影像表现者,血浆MMP-9升高提示肺功能加速下降和COPD发生风险较高,可考虑加强肺功能随访。
- 基线肺功能正常但MMP-9升高者,进展为COPD的风险增加,随访中应关注肺功能变化和急性加重。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The imbalance in proteases/antiproteases caused by inflammation contributes to COPD, and matrix metalloproteinase-9 (MMP-9) may play an important role. Therefore, we aimed to investigate the associations of MMP-9 with respiratory health outcomes. METHODS: This study was conducted in two parts. Firstly, we performed a prospective cohort study to investigate the association of circulating MMP-9 and respiratory health outcomes. Participants completed a questionnaire, spirometry, and chest CT, and provided blood samples at baseline. Follow-up visits were conducted annually. Study outcomes were the development of spirometry-defined COPD, lung function decline, and exacerbations. Secondly, we performed a two-sample Mendelian randomisation (MR) study to evaluate the causal effect between genetically predicted MMP-9 expression and lung function. RESULTS: Overall, 1328 participants were included in the baseline analysis, and 1034 (78%) completed the 2-year follow-up. Higher plasma MMP-9 at baseline was associated with chronic respiratory symptoms, severe emphysema, and air trapping. During the 2-year follow-up, each SD increase in plasma MMP-9 was associated with accelerated decline in pre-bronchodilator FEV1 (adjusted difference = 6.4 [95% CI: 0.7-12.1] mL/year) and FVC (adjusted difference = 18.0 [95% CI: 7.6-28.5] mL/year), and a higher exacerbation incidence. In participants with normal spirometry at baseline, higher plasma MMP-9 was associated with progression to spirometry-defined COPD (adjusted OR = 1.93, 95% CI: 1.05-3.57). A MR study demonstrated similar results toward negative associations of genetically predicted MMP-9 expression with FEV1 and FVC. CONCLUSION: The longitudinal cohort and MR study provide evidence that MMP-9 might play a causative role in lung function decline and spirometry-defined COPD development.
引用
- Ran, Wu, Wang, et al. Elevated MMP-9 Is Associated With Accelerated Lung Function Decline and COPD Development: A Prospective Cohort Study and Mendelian Randomisation Analysis. Respirology. 2025. PMID: 40765286. doi:10.1111/resp.70099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。